Alibaba to pay $600 million to settle US drug sales allegations

The U.S. Justice Department announced that a major e‑commerce platform has formally acknowledged its inability to stop the sale of approximately 80,000 illegal drug products through its marketplace. The admission follows a federal investigation that uncovered the presence of controlled substances, prescription medications without proper authorization, and other prohibited items listed by third‑party sellers. According to the department, the platform’s internal monitoring systems failed to detect and remove these listings in a timely manner, allowing the illicit products to reach consumers nationwide.

In response, the company has pledged to enhance its compliance protocols, including expanding automated detection tools, increasing human review capacity, and tightening seller verification procedures. The Justice Department indicated that it will continue to assess the platform’s remedial actions and may pursue further civil or criminal enforcement if the shortcomings persist. The case underscores ongoing regulatory scrutiny of online marketplaces and their role in preventing the distribution of illegal goods.